This event is organized with the aim to help member and/or non-member companies in finding suitable business partner for collaboration. RINK has diverse participation and collaboration from industry groups and related organizations, in order to promote the utilization and industrialization of regenerative medicine and cell therapy.
Date ：February 14, 2025（Fri）
Time ：1:00-9:00 p.m.
Venue：TIAT SKY HALL (Haneda Airport Terminal 3), TOKYO
Host ：Kanagawa Prefecture government
Host ：Regenerative medicine & Cell therapy industrialization network of Kanagawa (RINK)
Support：The Japanese Society for Regenerative Medicine（JSRM）
Support：Kansai Regenerative medicine Industrial Consortium（KRIC)
Participation fee (tax included, per person)：2,000 JPY
◆Registration: Registration is required in advance. Please sign up through Peatix (link to external site) below.
https://rinkfestival2025.peatix.com
〈Cancellation Policy〉
Cancellations, changes, or refunds are not available after purchasing tickets.
If the event is cancelled, the ticket fee paid will be refunded.
Program：
13:00 – 13:30 Opening Session
13:30 – 14:50 SessionＡ：To become a Japan’s Key Industry ; Create regenerative medicine and cell therapy！
15:00 – 16:20 SessionＢ：The future of regenerative medicine pioneered by AI
16:30 – 17:10 SessionＣ：Key preclinical & regulatory considerations for CGT products targeting the US market
17:20 – 18:20 SessionD：Ecosystem for the manufacture of regenerative medicine products
18:30 – 19:30 SessionE：Gathering of top runners in the regenerative medicine industry
19:30 – 21:00 Networking Party
【Opening Session】
Kosuke Kawai, General Manager, Regenerative Medicine Project, Air Separation Gases Dept., Industrial Gases Div., Iwatani Corporation / Organization for Advanced Healthcare Innovation
Kazuya Yoshida, Fellow, Innovation Division, Daidan Co., Ltd. / CEO, Cellab Healthcare Service CO.,LTD.
Nobuhiko Kojima, Professor, Graduate School of Nanobioscience, Yokohama City University
Shintaro Saito, Duputy Director, The Kansai Bureau of Economy, Trade and Industry (METI-KANSAI)
Kenichi Harada, Regenerative medicine & Cell therapy industrialization network of
Kanagawa (RINK)
【Session A】To become a Japan’s Key Industry ; Create regenerative medicine and cell therapy！
Yoshiyuki Makino, Executive Director of ME-BYO Industry, Inochi and Future Strategy Headquarters Office Policy Bureau, Kanagawa Prefectural Government
Ryuta Nomura, Chairman of the Board, Chief Executive Officer, Central Institute for Experimental Medicine and Life Science (CIEM) / Chairman, KING SKYFRONT Networking Council / Visiting professor, Fujita Health University
Yasunori Aizawa, Associate professor, School of Life Science and Technology, Institute of Science Tokyo / CSO, Logomix Inc.
Yuichi Tei, Vice President, Kanagawa University of Human Services / Professor, Department of Bioengineering, Graduate School of Engineering, Laboratory of Clinical Biotechnology, Center for Disease Biology and Integrative Medicine Graduate School of Medicine, University of Tokyo
Masaya Nakamura, Professor, Department of Orthopaedic Surcery School of Medicine, Keio University
【Session B】The future of regenerative medicine pioneered by AI
Yosuke Ozawa, CEO, Epistra Inc.
Takashi Suzuki, Group Leader, Cell Analysis Group, Cell Business Unit, Shimadzu Corporation
Hideto Yamaguchi, Senior Vice President, Head of Chemical & Biological Technology Labs, Astellas Pharma Inc.
Koichi Takahashi, Team Leader, RIKEN Center for Biosystems Dynamics Research
Ryuji Kato, Associate professor, Laboratory of Cell and Molecular Bioengineering, Division of Bioscience, Department of Basic Medical Sciences, Graduate School of Pharmaceutical Sciences, Nagoya University
【Session C】
Key preclinical & regulatory considerations for CGT products targeting the US market
Nate Manley, Senior Principal, Dark Horse Consulting Group, Inc.
Mayu Yoshikawa, Chief Strategy Officer, A-SEEDS Co., Ltd.
【Session D】Ecosystem for the manufacture of regenerative medicine products
Miho Kobayashi, Manager, Arthur D. Little (Japan)
Shin Kawamata, CEO, Cyto-Facto Inc.
Takashi Yamamoto, General Manager, Regenerative Medicine Business Strategy Department, Regenerative Medicine & Implantable Medical Devices Division, Teijin Limited
Hideki Nonaka, Group Manager, Regenerative Medicine Research & Planning Division, Rohto Pharmaceutical Co., Ltd.
Reina Kodera, Duputy Director, Bio-Industry Division, Commerce and Service Industry Policy Group, Ministry of Economy,Trade and Industry
【Session E】Gathering of top runners in the regenerative medicine industry
Shizuka Akieda, CEO, Cyfuse Biomedical K.K.
Takehiko Kaneko, Director & CMO, Heartseed Inc.
Shinji Uga, Executive Vice President & COO, Hirosaki LI Inc. (to be renamed CynosBio Inc. from February)
Honoka Kiso, CEO, Toregem Bio Pharma Co., Ltd.
Kenichi Harada, Regenerative medicine & Cell therapy industrialization network of
Kanagawa (RINK)
【Networking Party】
RINK FESTIVAL 2024 with LINK-J
＜Contact Us＞
The Regenerative medicine & Cell therapy industrialization network of
Kanagawa (RINK) Secretariat
Email: admin@rink.kanagawa.jp
